Lilly’s pill trailmblazes... just not as fast as Novo’s

First-week faceoff

Eli Lilly’s obesity pill just got compared with Novo Nordisk’s, and on the opening lap, Lilly’s drug looked a little like the kid who showed up to the race after tying its shoes. The headline? It lagged Novo’s pill in the first week.

So why did the stock rally?

Because investors aren’t just buying the first mile — they’re buying the whole road trip. If Lilly’s pill continues to show a cleaner safety profile and strong long-term upside, a slower start may not matter much in a market that’s still trying to figure out who owns the future of oral obesity drugs.

• The first-week data wasn’t a knockout punch for Lilly.
• But the market seemed more interested in the drug’s broader commercial potential.
• Any sign Lilly can build a massive obesity franchise without the baggage of older treatments is still a huge deal.

Big picture

This is the kind of stock move that reminds you Wall Street loves a good plot twist. A small stumble in week one doesn’t necessarily change the ending — especially when the prize is a blockbuster obesity market. Big picture: Lilly may have lost the opening lap, but investors are still betting it can win the race.